Key result
Elevated plasma hyaluronan is linked to pulmonary hypertension in heart failure and COPD.
Why the study?
The pathophysiologic mechanism of pulmonary arterial hypertension is unknown but may involve tissue remodeling and inflammatory processes involving hyaluronan.
Are plasma hyaluronan levels elevated in patients with pulmonary hypertension associated with CHF or COPD compared to healthy controls?
Cross-Sectional (n=48)
No
Are plasma hyaluronan levels elevated in patients with pulmonary hypertension associated with CHF or COPD compared to healthy controls?
Plasma hyaluronan levels are significantly elevated in patients with pulmonary hypertension associated with CHF or COPD, suggesting a potential role in the development of PAH.
Pulmonary arterial hypertension (PAH) is a progressive disease, with a poor prognosis. The pathophysiologic mechanism of PAH is unknown, but may involve both tissue remodeling and inflammatory processes. Hyaluronan (HA) is a large glycosaminoglycan polymer and a major component of the extracellular matrix. In the present study, we measured plasma HA levels in PAH associated with systolic congestive heart failure (CHF, n = 16) or chronic obstructive pulmonary disease (COPD, n = 18). The control group was consisted of 14 healthy individuals without pulmonary or cardiovascular disease. Plasma HA levels (ng/mL) were determined in all patients by an enzyme linked HA binding assay. Pulmonary arterial pressure (PAP) was calculated in echocardiography (mmHg). Pulmonary arterial pressures were significantly higher in CHF and COPD (CHF: 55.0 ± 11 mmHg and COPD: 62.5 ± 21 mmHg, p < 0.001 for each), compared to the control group (25.4 ± 5.9 mmHg). Plasma HA levels were significantly higher in CHF (73.0 ± 37.5 ng/ml, p = 0.007) and COPD (87.3 ± 53.2 ng/ml, p = 0.001) compared to control patients (26.2 ± 8.4 ng/ml). There was no significant difference in plasma HA levels between the CFH and COPD groups (p = 0.690). In COPD, plasma HA levels were significantly correlated with PAP, left atrium diameter. There was no significant correlation between plasma HA levels and age or with echocardiography parameters in CHF. Both CHF and COPD are associated with increased plasma HA levels. Elevated plasma HA may contribute to the development of PAH.
No takes yet. Share an insight, caveat, or question.
Kalay et al. (2013) conducted a cross-sectional in Pulmonary arterial hypertension (n=48). Congestive heart failure or COPD vs. Healthy controls was evaluated on Plasma hyaluronan (HA) levels (p=0.007 (CHF), 0.001 (COPD)). Plasma hyaluronan levels were significantly elevated in pulmonary arterial hypertension associated with heart failure (73.0 ng/mL) and COPD (87.3 ng/mL) compared to healthy controls (26.2 ng/mL).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: